'Choi Tae-won's Eldest Daughter' Choi Yoon-jung Appointed Executive... Promoted to Head of SK Biopharm Division

SK Biopharm Announces Organizational Restructuring and Personnel Changes

SK Biopharm announced on the 7th that it has carried out an organizational restructuring and executive appointments, newly appointing Choi Yoon-jung (photo), Head of the Business Development Division, as an executive.

Choi Yoon-jung, the new Head of Business Development at SK Biopharm.
[Photo by SK Biopharm]

Following the organizational restructuring, the research and development (R&D) sector has adopted an agile organizational system centered on projects rather than the existing organization-centered structure. SK Biopharm plans to establish a 'Global R&D Committee' for joint research between SK Biopharm and its U.S.-based research-focused subsidiary, SK Life Science Labs, and to expand its platforms. The new platforms to be expanded include cell and gene therapy (CGT), radiopharmaceutical therapy (RPT), and targeted protein degradation (TPD). Under the Business Development Division, the Business Development Team and the Strategic Investment Team have been integrated.

In this personnel appointment, Choi Yoon-jung, who previously led the Strategic Investment Team, was promoted to the new Head of the Business Development Division. Director Choi is the eldest daughter of SK Group Chairman Chey Tae-won. She graduated from Beijing International High School in China, majored in biology at the University of Chicago, and worked as a researcher at the University of Chicago Brain Science Institute and as a consultant at Bain & Company. She joined SK Biopharm in 2017 as a senior manager (assistant manager level) in the Strategy Team of the Management Strategy Office, took a leave of absence in 2019 to pursue a master's degree in bioinformatics at Stanford University in the U.S., and returned to work in July 2021. She was promoted to team leader of the Strategic Investment Team in the Global Investment Division last January.

SK Biopharm explained that this restructuring and personnel appointment aim to "enhance the efficiency, flexibility, and collaboration of research and development and to maximize synergy between business development and strategic investment."

Below is the list of promoted executives.

▲ Head of Business Development Division Choi Yoon-jung

This content was produced with the assistance of AI translation services.